This (Modecate) injection is being permanently discontinued. Production will cease in mid-2018, and the product is expected to remain available in the UK up until the end of 2018. All presentations will be withdrawn (Modecate 25mg/ml and Modecate concentrate injection 100mg/ml) - further information available on the APC newsfeed

Haloperidol decanoate

Formulary

Treatment of schizophrenia and other psychoses

Zuclopenthixol decanoate

Formulary

Treatment of schizophrenia and other psychoses, particularly with aggression and agitation

Treatment of schizophrenia in patients who have been stabilised on monthly paliperidone long acting injection for at least 12 months, specialist to complete SIDC

An exception to this would be patients already stabilised on the one monthly injection within primary care. Primary care could consider switching to the three monthly depot injection in line with the Drug Position Statement, the SPC and the checklist for assurance

Currently not available in CWPT except for when in-line with CWPT criteria then to be used as

Key

Notes

Section Title (top level)

Section Title (sub level)

First Choice item

Non Formulary section

Restricted Drug

Unlicensed

Display tracking information

Link to adult BNF

Link to children's BNF

Link to SPCs

Scottish Medicines Consortium

Cytotoxic Drug

Controlled Drug

High Cost Medicine

High Cost Drug Approval System

Traffic Light Status Information

Status

Description

Clinicians are free to prescribe these drugs. They are regarded as cost effective choices which have evidence to support their use.

These drugs should only be prescribed in the scenarios described in the formulary after preferred drug(s) have been ruled out.

Non-formulary choice - the vast majority of a patientís needs should be met by use of formulary preferred choices and second line options when appropriate. Therefore the Clinician should only use a non-formularly drug if this can be justified and it is recommended that all such instances are recorded in the patient record.

Specialist Advised Ė
Specialists may simply advise a patientís GP to initiate these drugs themselves after they have made an initial assessment.
Note: SA drugs can be initiated by the specialist according to patient need and also depending on local commissioning arrangements which may mandate, through the contract between provider and commissioner, that all SA drugs are treated as SI.

Specialist Initiation -
These drugs must be initiated, i.e. the first dose prescribed, by the specialist and then may be continued when appropriate by the patientís GP following communication from the specialist.

Shared Care -
Responsibility for prescribing may be transferred from secondary to primary care with the agreement of an individual GP and when agreed shared care arrangements have been established. The specialist MUST stabilize the patient before asking for care to be transferred.
Only specialists should initiate these drugs. Prescribing should be transferred to GPs according to an Shared Care Agreement [SCA]

Specialist Only -
These drugs are deemed to be not appropriate for prescribing by GPs.
Specialists should not ask GPs to prescribe these drugs.

Black Listed Medicines - These drugs are considered inappropriate for prescribing in Coventry & Warwickshire as they are either not cost-effective or of proven benefit or both.

Not Recommended - These are specialist drugs that are not recommended for use.